Channavix Therapeutics and Peregrine BioVentures are developing two patent families related to long-lasting, non-opioid, non-addictive pain therapeutics.
'I would like to express our university’s solidarity with UB’s Iranian students and faculty as well as our concern for the safety and liberty of their loved ones in their home country,' he says.